证券代码：600252 证券简称：中恒集团 公告编号：临 2026-9 广西梧州中恒集团股份有限公司 关于控股孙公司收到执行裁定书的公告 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 案件所处的诉讼阶段：经和解后孙公司申请撤销执行。 上市公司所处的当事人地位：成都金星健康药业有限公司（以下简称"成 都金星"）为本案的原告，成都金星系广西梧州中恒集团股份有限公司（以下简 称"公司"或"中恒集团"）的控股孙公司。 是否会对上市公司损益产生负面影响：本次执行裁定事项不会对公司本 期利润产生重大不利影响，不存在损害公司及股东利益的情形。 敬请投资者谨慎决策，注意投资风险。 一、前期诉讼事项的基本情况 公司控股子公司重庆莱美药业股份有限公司及其控股子公司成都金星与 成都耀匀医药科技有限公司（以下简称"耀匀医药"）的诉讼事项，因耀匀 医药未履行法院生效的一审判决，成都金星遂向四川自由贸易试验区人民法 院（以下简称"四川自贸试验区法院"）申请执行。后相关各方经协商，就 该诉讼及增资协议履行等事项达成和解，并于 2025 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2026-10 广西梧州中恒集团股份有限公司 关于控股孙公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"） 控股子公司重庆莱美药业股份有限公司的全资子公司湖南康源制药有限公司（以 下简称"湖南康源"）收到国家药品监督管理局核准签发的乳酸钠林格注射液（规 格：500ml）《药品补充申请批准通知书》，现将有关事宜公告如下： 1 药品名称 通用名称：乳酸钠林格注射液 英文名/拉丁名：Sodium Lactate Ringer's Injection 剂型 注射剂 注册分类 化学药品 规格 500ml 原药品批准文号 国药准字 H20084559 包装规格 30 袋/箱 药品注册标准编号 YBH01872026 申请内容 注射剂仿制药质量和疗效一致性评价，其他变更事项包括：1.变更药 品处方及生产工艺（含原料药供应商）；2.变更药品质量标准（含贮 藏条件与有效期）；3.变更直 ...

中恒集团晚间公告，控股孙公司成都金星与耀匀医药诉讼达成和解后，申请撤销执行并收到法院执行裁 定书，裁定解除对耀匀医药名下账号的冻结，该事项不影响公司本期利润及股东利益。 ...

Core Viewpoint - Zhongheng Group's subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the sodium lactate Ringer's injection (specification: 500ml) [1] Group 1 - The drug has passed the consistency evaluation of quality and efficacy for generic drugs [1] - The approval allows for changes in the drug formulation, production process, quality standards, packaging materials, and container [1] - The effective period of the approval is 18 months [1] Group 2 - The original drug approval number is valid until July 16, 2028 [1] - Hunan Kangyuan Pharmaceutical Co., Ltd. is located at No. 8 Kangping Road, Liuyang Economic and Technological Development Zone, Hunan Province [1]

Group 1 - The core announcement is about the approval of the ethical review for the Phase II clinical trial of "Nano Carbon Iron Suspension Injection" by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., a subsidiary of Chongqing Laimei Pharmaceutical Co., Ltd., which is controlled by Guangxi Wuzhou Zhongheng Group Co., Ltd. [1] - The Phase I clinical trial of Nano Carbon Iron has been successfully completed, focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors [1][2] - The Phase II clinical trial aims to validate the effectiveness and safety of the drug in combination with radiotherapy, providing critical data for the final product application [1][3] Group 2 - Nano Carbon Iron is a next-generation nano drug developed based on the company's existing product, utilizing Fe2+ as an effective anti-cancer component and nano carbon as a carrier, targeting the iron death pathway to exert anti-cancer effects [3] - The drug is administered intratumorally and is expected to enhance the efficacy of radiotherapy, particularly in large, hypoxic tumors that are difficult to control with radiotherapy alone [3] - As of the announcement date, the cumulative R&D expenses for Nano Carbon Iron amount to approximately 98.06 million RMB (data unaudited) [4]

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has successfully passed the ethical review for its self-developed "Nano Carbon Iron Suspension Injection," marking the entry into Phase II clinical trials for combined therapy with radiotherapy [1] Group 1: Clinical Trial Progress - The Phase I clinical trial of Nano Carbon Iron has been completed, focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors [1] - The Ib/IIa phase clinical trial has partially enrolled subjects, with ongoing efficacy follow-ups to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple doses of Nano Carbon Iron in advanced solid tumor patients [1] - The Phase II clinical trial will validate the effectiveness and safety of the drug in combination therapy, providing critical data support for the final product launch application [1] Group 2: Preparatory Work - Yingrui Pharmaceutical is actively preparing for the necessary work before the launch of the research center to ensure the smooth progress of the trials [1]

Group 1 - The company Zhongheng Group announced that as of the date of the announcement, the actual external guarantee balance of the company and its subsidiaries is approximately 244 million yuan, which accounts for 4.06% of the company's audited net assets attributable to shareholders for 2024 [1]

证券代码：600252 证券简称：中恒集团 公告编号：临 2026-7 广西梧州中恒集团股份有限公司 关于为全资子公司中恒医药提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供的担 保余额（不含本次 | 是否在前期 | 本次担保是 | | --- | --- | --- | --- | --- | | | （最高额） | 担保金额） | 预计额度内 | 否有反担保 | | 广西梧州市中恒医药有 | | | | | | 限公司（以下简称"中 | 1,000.00 万元 | | 0 是 | 否 | | 恒医药"） | | | | | 为满足广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"） 全资子公司中恒医药日常经营和业务发展需求，确保中恒医药生产经营活动的顺 利开展，公司为中恒医药向金融机构申请融资提供连带责任保证，具体情况如下： 1 2026 年 1 月 30 日，公司与交通银行股份有限公司梧州分行（以下简称"交 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2026-8 广西梧州中恒集团股份有限公司 关于控股孙公司纳米炭铁混悬注射液联合放疗 II 期 临床试验获得伦理批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"） 控股子公司重庆莱美药业股份有限公司（以下简称"莱美药业"）之子公司四川 瀛瑞医药科技有限公司（以下简称"瀛瑞医药"）自主研发的"纳米炭铁混悬注 射液"（以下简称"纳米炭铁"）于近期在四川大学华西医院顺利通过了伦理审 查并收到了临床试验伦理审查委员会的正式批件，标志着纳米炭铁联合放疗正式 进入 II 期临床试验阶段。现将相关情况公告如下： 一、纳米炭铁临床试验进展情况 截至本公告披露日，瀛瑞医药对纳米炭铁的累计研发费用化 9,805.85 万元人 民币（数据未经审计）。 三、风险提示 瀛瑞医药将按国家临床试验的相关要求组织开展纳米炭铁联合放疗的 II 期 临床试验，药品研发是项长期工作，受到技术、审批、政策等多方面因素的影响， II ...

Core Viewpoint - Zhongheng Group announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has successfully passed the ethical review for its independently developed "Nano Carbon Iron Suspension Injection," marking the entry into Phase II clinical trials in collaboration with radiotherapy [1] Group 1 - The "Nano Carbon Iron Suspension Injection" has received formal approval from the Clinical Trial Ethics Review Committee [1] - The clinical trials are being conducted at West China Hospital of Sichuan University [1] - This development signifies a significant advancement in the company's research and development efforts in the pharmaceutical sector [1]